74134-89-7 Usage
Uses
Used in Pharmaceutical Industry:
D-[UL-13C6]GALACTOSE is used as a tracer compound for monitoring the metabolism and utilization of galactose in the human body. Its stable isotope labeling allows for easier detection and tracking of the compound in various metabolic pathways.
Used in Medical Research:
D-[UL-13C6]GALACTOSE is used as a research tool for studying the role of galactose in various biological processes and diseases. The stable isotope labeling enables researchers to better understand the mechanisms of action and potential therapeutic applications of galactose-related compounds.
Used in Oral Therapy for Nephrotic Syndrome:
D-[UL-13C6]GALACTOSE is used as a potential therapeutic agent for oral therapy in patients with nephrotic syndrome, particularly in those with focal and segmental glomerulosclerosis. The stable isotope labeling allows for better monitoring of the compound's effects and its impact on the disease progression.
Check Digit Verification of cas no
The CAS Registry Mumber 74134-89-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,1,3 and 4 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 74134-89:
(7*7)+(6*4)+(5*1)+(4*3)+(3*4)+(2*8)+(1*9)=127
127 % 10 = 7
So 74134-89-7 is a valid CAS Registry Number.
74134-89-7Relevant articles and documents
STABILIZED ACYCLIC SACCHARIDE COMPOSITE AND METHOD FOR STABILIZING ACYCLIC SACCHARIDES AND APPLICATIONS THEREOF
-
, (2022/03/14)
Disclosed is a stabilized acyclic saccharide composite, which includes a LDH-based (layered double hydroxide-based) material and acyclic saccharides intercalated in interlayer regions of the LDH-based material. The acyclic saccharides stabilized and trapped in the LDH-based material give an opportunity for direct functionalization to other valuable molecules in the pharmaceutical, chemical or carbohydrate industries. Further, a novel pathway for saccharide transformation and aldol condensation without the drawbacks associated with enzymatic catalysts is achieved through the acyclic saccharides trapped by the LDH-based material.
